Inactivating EVI1 for the Treatment of Myelodysplastic *

灭活 EVI1 用于治疗骨髓增生异常*

基本信息

  • 批准号:
    7022781
  • 负责人:
  • 金额:
    $ 38.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-09-30 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by Applicant): Myelodysplastic syndrome (MDS) is a group of stem cell malignancies most frequent among elderly patients and has a high annual incidence among hematological malignancies with approximately 14,000 new cases diagnosed every year. About 30%-40% of MDS progresses to acute myeloid leukemia (AML). However, the majority of patients succumb from infection or bleeding or treatment complications within 3-5 years. With the increase of life expectancy due to improving medical care, there has been a significant increase in the frequency of MDS and at this time the incidence of MDS (about 5 per 100,000) is higher than that of chronic myelogenous leukemia (CML) or AML in the same age group. The genetic events that drive this disease are not known, however a translocation of chromosome band 3 q26 is a recurring abnormality seen in about 10% of MDS. This genomic site contains EVI1, a gene inappropriately activated in MDS by the chromosomal rearrangement. EVI1-positive MDS patients develop fatal hematopoietic defects rapidly evolving to AML and in general their survival is less than one year. In terms of the biological mechanisms which characterize MDS, it is generally thought that the MDS cell has impaired differentiation and increased apoptosis. As the disease evolves, the cells have increased deregulated proliferation and decreased apoptosis, remain immature, and the number of blast cells increases. The lack of an animal model that reproduces MDS has strongly limited our understanding of this disease. Recent work by our group has generated a significant animal model of MDS by forcing the expression of EVI1 in murine bone marrow (BM) cells. The mice show features of MDS including hypercellular BM, BM apoptosis, and severe cytopenia and anemia. In contrast to what observed in patients, the EVI1-ppsitive murine MDS does not evolve to AML and therefore provides a unique system to understand the disease at a stage which is still potentially treatable. Preliminary studies with this model have given clear clues about molecular pathways that affect erythropoiesis, platelet formation, and cell cycling immediately after expression of EVI1 and suggest that in the EVI1-positive mice the disease progresses from a viable early stage in which the erythropoietic lineage is compromised, to an always fatal late stage characterized by anemia, apoptosis, severe cytopenia, BM apoptosis, leading to death. The specific aims are designed to identify key steps in this progression that could be used to block the advancement of MDS and to follow the response to treatment of MDS patients. They include the identification of the molecular pathways that disrupt hematopoiesis in EVI1-positive BM cells (first aim) and of the genes that are activated or repressed by EVI1 (second aim). The third aim will be focused on the role of arsenic trioxide in the treatment of EVI1-positive MDS and on the isolation of small molecules that inhibit EVI1.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Giuseppina Nucifora其他文献

Giuseppina Nucifora的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Giuseppina Nucifora', 18)}}的其他基金

A Mouse Model of Myelodysplastic Syndrome Progression
骨髓增生异常综合征进展的小鼠模型
  • 批准号:
    7465550
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
Inactivating EVI1 for the Treatment of Myelodysplastic *
灭活 EVI1 用于治疗骨髓增生异常 *
  • 批准号:
    7487814
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
Inactivating EVI1 for the Treatment of Myelodysplastic *
灭活 EVI1 用于治疗骨髓增生异常 *
  • 批准号:
    7278665
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
A Mouse Model of Myelodysplastic Syndrome Progression
骨髓增生异常综合征进展的小鼠模型
  • 批准号:
    7650235
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
Inactivating EVI1 for the Treatment of Myelodysplastic *
灭活 EVI1 用于治疗骨髓增生异常 *
  • 批准号:
    7128100
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
A Mouse Model of Myelodysplastic Syndrome Progression
骨髓增生异常综合征进展的小鼠模型
  • 批准号:
    7082227
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
A Mouse Model of Myelodysplastic Syndrome Progression
骨髓增生异常综合征进展的小鼠模型
  • 批准号:
    6984724
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
A Mouse Model of Myelodysplastic Syndrome Progression
骨髓增生异常综合征进展的小鼠模型
  • 批准号:
    7261916
  • 财政年份:
    2005
  • 资助金额:
    $ 38.75万
  • 项目类别:
EVI1 Expression is a Prognostic Marker of CML
EVI1 表达是 CML 的预后标志物
  • 批准号:
    6750118
  • 财政年份:
    2003
  • 资助金额:
    $ 38.75万
  • 项目类别:
EVI1 Expression is a Prognostic Marker of CML
EVI1 表达是 CML 的预后标志物
  • 批准号:
    6610092
  • 财政年份:
    2003
  • 资助金额:
    $ 38.75万
  • 项目类别:

相似海外基金

Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
  • 批准号:
    10751106
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
Long-term exposure to arsenic, and the co-occurrence of uranium, in public and private drinking water: associations with cardiovascular and chronic kidney diseases in the California Teachers Study
公共和私人饮用水中长期接触砷以及同时存在铀:加州教师研究中与心血管和慢性肾脏疾病的关联
  • 批准号:
    10677410
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Programming of Epigenetic Clocks and Biomarkers from Early-life Arsenic Exposure
生命早期砷暴露的表观遗传时钟和生物标志物的编程
  • 批准号:
    10726009
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Exposure to Mixtures of Emerging Contaminants in the Environment - Are Communities in Uganda at Health Risk?- A Case Study of Mbarara City.
接触环境中新兴污染物的混合物 - 乌干达的社区面临健康风险吗? - 姆巴拉拉市的案例研究。
  • 批准号:
    10732272
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Latent profiles of prenatal exposure to toxic metals and psychosocial risk and protective factors: testing associations with child developmental outcomes and moderations by caregiving experience
产前接触有毒金属和心理社会风险和保护因素的潜在特征:测试与儿童发育结果的关联以及护理经验的调节
  • 批准号:
    10606183
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Bayesian Statistical Learning for Robust and Generalizable Causal Inferences in Alzheimer Disease and Related Disorders Research
贝叶斯统计学习在阿尔茨海默病和相关疾病研究中进行稳健且可推广的因果推论
  • 批准号:
    10590913
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Plant-mediated arsenic-iron mineral transformations
植物介导的砷铁矿物转化
  • 批准号:
    IN230100031
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Discovery Indigenous
Migration of arsenic and uranium in environments during iron transformation
铁转化过程中环境中砷和铀的迁移
  • 批准号:
    23K13693
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of arsenic-contaminated groundwater purification technology to secure safe water resources in the Mekong Delta
开发砷污染地下水净化技术确保湄公河三角洲水资源安全
  • 批准号:
    23KK0199
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Fund for the Promotion of Joint International Research (International Collaborative Research)
Field Instrument for Assessment of Arsenic Exposure
砷暴露评估现场仪器
  • 批准号:
    10484041
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了